Late-breaking oral presentation to highlight further evidence supporting potential for deupirfenidone to serve as a new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF) ...

PureTech Health plc ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the Company will ...

Pulmonary fibrosis (PF) is a progressive interstitial lung disease (ILD) characterized by excessive fibrotic tissue ...

Environmental and Occupational Exposure: Chronic inhalation of inorganic and organic particulates, such as silica, asbestos, ...

Multi-modal data integration of single-nuclei RNA and ATAC sequencing with spatial transcriptomics, provides new molecular insights into gene regulatory networks driving cell state transitions in ...

According to Wells Fargo, while the program has its merits, there are challenges in proving its success if the efficacy observed is not due to an actual antifibrotic effect. The analysts expressed ...

According to DevelInsight analysis, the estimated total diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM ...

Despite these antifibrotic treatments being available for a decade, mortality remains high, with an average survival time of only three to five years from diagnosis. There are also several side ...

Empirical treatment consists of corticosteroid and immunosuppressive agents. Antifibrotic agents may be successful in the future. This is generally a nonsteroid-responsive lesion and for disabling ...

Intercept tweaked the protocol for REGENERATE, and reported new results in 2022 which it now maintains show a “strong and confirmed antifibrotic effect” of OCA in this patient setting.

Nintedanib is a potent antifibrotic angiokinase inhibitor approved for various fibrotic lung diseases. Potential therapeutic efficacy of nintedanib in various inflammatory diseases is under ...